Developing Treatments for Inflammatory Diseases

We are advancing verekitug, a clinical-stage monoclonal antibody targeting an upstream driver of inflammatory response. Our experienced team is committed to leveraging verekitug’s unique mechanism of action to improve the treatment options for millions of patients living with severe inflammatory diseases.